arlutz73 Bristol-Myers Squibb ( NYSE: BMY ) said it has received EU approval for its drug Opdivo as a first-line treatment for adults with unresectable or metastatic urothelial carcinoma, a type of bladder cancer. The drug was approved for use in combination with cisplatin and gemcitabine, according to the company . Also known as nivolumab, Opdivo is also approved in the EU for the treatment of ten different cancers, including non-small cell lung cancer, colorectal cancer and kidney cancer.
More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo Bristol-Myers Squibb snaps six days of losses, trades in the green.
